Comparing dual trigger methods for oocyte maturation in donors
The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger
NA · Embryolab Fertility Clinic · NCT06142708
This study is testing a new method for helping egg donors produce better quality eggs by using a combination of two medications instead of just one.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 20 Years to 30 Years |
| Sex | Female |
| Sponsor | Embryolab Fertility Clinic (other) |
| Locations | 1 site (Thessaloniki) |
| Trial ID | NCT06142708 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of a dual trigger method, combining GnRH agonist and hCG, for final oocyte maturation in donors who previously had a suboptimal response to GnRH agonist alone. Participants will undergo controlled ovarian stimulation using a GnRH antagonist protocol, and the study will compare maturation rates, fertilization rates, embryo quality, and other key outcomes between the two triggering methods. The goal is to determine if the dual trigger can enhance oocyte yield and competency in these specific donors.
Who should consider this trial
Good fit: Ideal candidates are oocyte donors aged 18-25 with a history of suboptimal response to GnRH agonist trigger in previous cycles.
Not a fit: Patients at risk for ovarian hyperstimulation syndrome (OHSS) will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve oocyte yield and quality for donors with a history of suboptimal response, enhancing the chances of successful fertility treatments.
How similar studies have performed: While the dual trigger approach has been explored in other contexts, this specific application for oocyte donors with suboptimal responses is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI: 18 - 25 * AMH: 1-3ng/ml * AFC: 15 * Peak E2 in previous ovarian stimulation cycle: \< 4000 pg/ml * Ovarian response in first stimulation cycle: \< 20 follicles over 10mm in total, at time of triggering * Peak E2 in study cycle: \< 4000 pg/ml * Suboptimal response to trigger medication at first stimulation cycle * Male age \< 50 years old with normospermia Exclusion Criteria: * Oocyte donors which are at risk for development of ovarian hyperstimulation syndrome (OHSS)
Where this trial is running
Thessaloniki
- Embryolab Fertility Clinic — Thessaloniki, Greece (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ovarian Stimulation, Human Chorionic Gonadotropin, Oocyte Donors, GnRH agonist, Dual trigger